Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis

There is currently no therapy impacting the course of amyotrophic lateral sclerosis (ALS). The only approved treatments are riluzole and edaravone, but their efficacy is modest and short‐lasting, highlighting the need for innovative therapies. We previously demonstrated the ability of PXT864, a comb...

Descripción completa

Detalles Bibliográficos
Autores principales: Boussicault, Lydie, Laffaire, Julien, Schmitt, Peter, Rinaudo, Philippe, Callizot, Noëlle, Nabirotchkin, Serguei, Hajj, Rodolphe, Cohen, Daniel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693228/
https://www.ncbi.nlm.nih.gov/pubmed/32815196
http://dx.doi.org/10.1002/jnr.24714

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693228/
https://www.ncbi.nlm.nih.gov/pubmed/32815196
http://dx.doi.org/10.1002/jnr.24714

Ejemplares similares